Serelaxin in acute heart failure patients with and without atrial fibrillation

a secondary analysis of the RELAX-AHF trial

Gerasimos Filippatos, Dimitrios Farmakis, Marco Metra, Gad Cotter, Beth A. Davison, G. Michael Felker, Barry H. Greenberg, Tsushung A. Hua, Peter Pang, Piotr Ponikowski, Min Qian, Thomas A. Severin, Adriaan A. Voors, John R. Teerlink

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Atrial fibrillation (AFib) is a common comorbidity in HF and affects patients’ outcome. We sought to assess the effects of serelaxin in patients with and without AFib. Methods: In a post hoc analysis of the RELAX-AHF trial, we compared the effects of serelaxin on efficacy end points, safety end points and biomarkers in 1161 patients with and without AFib on admission electrocardiogram. Results: AFib was present in 41.3% of patients. Serelaxin had a similar effect in patients with and without AFib, including dyspnea relief by visual analog scale through day 5 [mean change in area under the curve, 541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 (−63.30, 786.90), p = 0.0953 in non-AFib, interaction p = 0.5954] and all-cause death through day 180 [HR = 0.42 (0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin was similarly safe in the two groups and induced similar reductions in biomarkers of cardiac, renal and hepatic damage. Stroke occurred more frequently in AFib patients (2.8 vs. 0.8%, p = 0.0116) and there was a trend for lower stroke incidence in the serelaxin arm in AFib patients (odds ratios, 0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, interaction p = 0.0518). Conclusions: Serelaxin was similarly safe and efficacious in improving short- and long-term outcomes and inducing organ protection in acute HF patients with and without AFib.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalClinical Research in Cardiology
DOIs
StateAccepted/In press - Feb 1 2017

Fingerprint

Atrial Fibrillation
Heart Failure
Biomarkers
Stroke
Visual Analog Scale
Dyspnea
Area Under Curve
Comorbidity
Cause of Death
Electrocardiography
Odds Ratio
Kidney
Safety
Liver
Incidence

Keywords

  • Acute heart failure
  • Atrial fibrillation
  • Relaxin
  • Serelaxin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Filippatos, G., Farmakis, D., Metra, M., Cotter, G., Davison, B. A., Felker, G. M., ... Teerlink, J. R. (Accepted/In press). Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clinical Research in Cardiology, 1-13. https://doi.org/10.1007/s00392-016-1074-x

Serelaxin in acute heart failure patients with and without atrial fibrillation : a secondary analysis of the RELAX-AHF trial. / Filippatos, Gerasimos; Farmakis, Dimitrios; Metra, Marco; Cotter, Gad; Davison, Beth A.; Felker, G. Michael; Greenberg, Barry H.; Hua, Tsushung A.; Pang, Peter; Ponikowski, Piotr; Qian, Min; Severin, Thomas A.; Voors, Adriaan A.; Teerlink, John R.

In: Clinical Research in Cardiology, 01.02.2017, p. 1-13.

Research output: Contribution to journalArticle

Filippatos, G, Farmakis, D, Metra, M, Cotter, G, Davison, BA, Felker, GM, Greenberg, BH, Hua, TA, Pang, P, Ponikowski, P, Qian, M, Severin, TA, Voors, AA & Teerlink, JR 2017, 'Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial', Clinical Research in Cardiology, pp. 1-13. https://doi.org/10.1007/s00392-016-1074-x
Filippatos, Gerasimos ; Farmakis, Dimitrios ; Metra, Marco ; Cotter, Gad ; Davison, Beth A. ; Felker, G. Michael ; Greenberg, Barry H. ; Hua, Tsushung A. ; Pang, Peter ; Ponikowski, Piotr ; Qian, Min ; Severin, Thomas A. ; Voors, Adriaan A. ; Teerlink, John R. / Serelaxin in acute heart failure patients with and without atrial fibrillation : a secondary analysis of the RELAX-AHF trial. In: Clinical Research in Cardiology. 2017 ; pp. 1-13.
@article{eb60a9ebef9d4807a98f4590b5b95087,
title = "Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial",
abstract = "Background: Atrial fibrillation (AFib) is a common comorbidity in HF and affects patients’ outcome. We sought to assess the effects of serelaxin in patients with and without AFib. Methods: In a post hoc analysis of the RELAX-AHF trial, we compared the effects of serelaxin on efficacy end points, safety end points and biomarkers in 1161 patients with and without AFib on admission electrocardiogram. Results: AFib was present in 41.3{\%} of patients. Serelaxin had a similar effect in patients with and without AFib, including dyspnea relief by visual analog scale through day 5 [mean change in area under the curve, 541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 (−63.30, 786.90), p = 0.0953 in non-AFib, interaction p = 0.5954] and all-cause death through day 180 [HR = 0.42 (0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin was similarly safe in the two groups and induced similar reductions in biomarkers of cardiac, renal and hepatic damage. Stroke occurred more frequently in AFib patients (2.8 vs. 0.8{\%}, p = 0.0116) and there was a trend for lower stroke incidence in the serelaxin arm in AFib patients (odds ratios, 0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, interaction p = 0.0518). Conclusions: Serelaxin was similarly safe and efficacious in improving short- and long-term outcomes and inducing organ protection in acute HF patients with and without AFib.",
keywords = "Acute heart failure, Atrial fibrillation, Relaxin, Serelaxin",
author = "Gerasimos Filippatos and Dimitrios Farmakis and Marco Metra and Gad Cotter and Davison, {Beth A.} and Felker, {G. Michael} and Greenberg, {Barry H.} and Hua, {Tsushung A.} and Peter Pang and Piotr Ponikowski and Min Qian and Severin, {Thomas A.} and Voors, {Adriaan A.} and Teerlink, {John R.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s00392-016-1074-x",
language = "English (US)",
pages = "1--13",
journal = "Clinical Research in Cardiology",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",

}

TY - JOUR

T1 - Serelaxin in acute heart failure patients with and without atrial fibrillation

T2 - a secondary analysis of the RELAX-AHF trial

AU - Filippatos, Gerasimos

AU - Farmakis, Dimitrios

AU - Metra, Marco

AU - Cotter, Gad

AU - Davison, Beth A.

AU - Felker, G. Michael

AU - Greenberg, Barry H.

AU - Hua, Tsushung A.

AU - Pang, Peter

AU - Ponikowski, Piotr

AU - Qian, Min

AU - Severin, Thomas A.

AU - Voors, Adriaan A.

AU - Teerlink, John R.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Atrial fibrillation (AFib) is a common comorbidity in HF and affects patients’ outcome. We sought to assess the effects of serelaxin in patients with and without AFib. Methods: In a post hoc analysis of the RELAX-AHF trial, we compared the effects of serelaxin on efficacy end points, safety end points and biomarkers in 1161 patients with and without AFib on admission electrocardiogram. Results: AFib was present in 41.3% of patients. Serelaxin had a similar effect in patients with and without AFib, including dyspnea relief by visual analog scale through day 5 [mean change in area under the curve, 541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 (−63.30, 786.90), p = 0.0953 in non-AFib, interaction p = 0.5954] and all-cause death through day 180 [HR = 0.42 (0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin was similarly safe in the two groups and induced similar reductions in biomarkers of cardiac, renal and hepatic damage. Stroke occurred more frequently in AFib patients (2.8 vs. 0.8%, p = 0.0116) and there was a trend for lower stroke incidence in the serelaxin arm in AFib patients (odds ratios, 0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, interaction p = 0.0518). Conclusions: Serelaxin was similarly safe and efficacious in improving short- and long-term outcomes and inducing organ protection in acute HF patients with and without AFib.

AB - Background: Atrial fibrillation (AFib) is a common comorbidity in HF and affects patients’ outcome. We sought to assess the effects of serelaxin in patients with and without AFib. Methods: In a post hoc analysis of the RELAX-AHF trial, we compared the effects of serelaxin on efficacy end points, safety end points and biomarkers in 1161 patients with and without AFib on admission electrocardiogram. Results: AFib was present in 41.3% of patients. Serelaxin had a similar effect in patients with and without AFib, including dyspnea relief by visual analog scale through day 5 [mean change in area under the curve, 541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 (−63.30, 786.90), p = 0.0953 in non-AFib, interaction p = 0.5954] and all-cause death through day 180 [HR = 0.42 (0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin was similarly safe in the two groups and induced similar reductions in biomarkers of cardiac, renal and hepatic damage. Stroke occurred more frequently in AFib patients (2.8 vs. 0.8%, p = 0.0116) and there was a trend for lower stroke incidence in the serelaxin arm in AFib patients (odds ratios, 0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, interaction p = 0.0518). Conclusions: Serelaxin was similarly safe and efficacious in improving short- and long-term outcomes and inducing organ protection in acute HF patients with and without AFib.

KW - Acute heart failure

KW - Atrial fibrillation

KW - Relaxin

KW - Serelaxin

UR - http://www.scopus.com/inward/record.url?scp=85011295569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011295569&partnerID=8YFLogxK

U2 - 10.1007/s00392-016-1074-x

DO - 10.1007/s00392-016-1074-x

M3 - Article

SP - 1

EP - 13

JO - Clinical Research in Cardiology

JF - Clinical Research in Cardiology

SN - 1861-0684

ER -